Ofatumumab vs Ublituximab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanism: CD20 · full Multiple Sclerosis pipeline
Ofatumumab
Marketed by Novartis and partners
NCT02792231 · Phase 3 · completed
This was a large, randomized, quadruple-blind, active-controlled trial of 955 participants, comparing ofatumumab with teriflunomide. The prespecified primary clinical endpoint, annualized confirmed relapse rate, was significantly better with ofatumumab (p<0.001), supporting a strong evidence grade despite mixed findings for some secondary measures.
Next expected readout: April 2027 · NCT05090371 (registry estimate)
Reported efficacy
Annualized Relapse Rate (ARR) (Baseline up to 2.5 years): Annualized Relapse Rate (ASCLEPIOS II): 0.10 (ofatumumab) vs 0.25 (teriflunomide); difference -0.15 (95% CI: -0.20, -0.09) (met)
Result source: NCT02792231
Ublituximab · Briumvi
Marketed by TG THERAPEUTICS, INC. and partners
NCT03277261 · Phase 3 · completed
This was a randomized, quadruple-masked, active-controlled trial of 549 participants, with ublituximab and teriflunomide administered alongside matching placebos. The primary clinical endpoint was met: ublituximab produced a significantly lower annualized relapse rate than teriflunomide through 96 weeks (p<0.0001).
Next expected readout: January 2027 · NCT05877963 (registry estimate)
Reported efficacy
Annualized Relapse Rate (ARR) (Up to 96 weeks): Annualized Relapse Rate (ARR) (Up to 96 weeks): Ublituximab + Oral Placebo 0.091 relapses per participant-years (95% CI 0.049 to 0.169) vs Teriflunomide + IV Placebo 0.178 relapses per participant-years (95% CI 0.109 to 0.291) (met)
Result source: NCT03277248
Results for Multiple Sclerosis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Ofatumumab | Ublituximab |
|---|---|---|
| Annualised relapse rate | 0.1 vs 0.3vs TERNCT027922314 other results
| 0.1 vs 0.2vs TeriflunomideNCT032772611 other result
|
| Free of 3-month confirmed disability progression (%) | —Not posted · NCT04788615 | —Trial running · NCT07220252 |
| New or enlarging T2 lesions | —Not posted · NCT04788615 | —Trial running · NCT07220252 |
Annualised relapse rate
- Ofatumumab
- 0.1 vs 0.3vs TERNCT02792231
4 other results
- 0.1 vs 0.2 NCT02792218
- 0.1 vs 0.2 NCT02792231
- 0.1 vs 0.2 NCT02792218
- 0.3 vs 0.6 NCT03249714
- Ublituximab
- 0.1 vs 0.2vs TeriflunomideNCT03277261
1 other result
- 0.1 vs 0.2 NCT03277248
Free of 3-month confirmed disability progression (%)
- Ofatumumab
- —Not posted · NCT04788615
- Ublituximab
- —Trial running · NCT07220252
New or enlarging T2 lesions
- Ofatumumab
- —Not posted · NCT04788615
- Ublituximab
- —Trial running · NCT07220252
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety
Coverage. Ofatumumab: 6 of 6 rows · Ublituximab: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ofatumumab Rows use multiple source trials | Ublituximab Rows use multiple source trials |
|---|---|---|
| Annualized Relapse event rate · per year No placebo or comparator arm | 0.06 per yeara,b,c,d NCT04353492 · Phase 3 · registry result, not featured evidence | 0.28 per year @ 48wke,a,b,c,d NCT02738775 · Phase 2 · registry result, not featured evidence show 5 more doses0 per year @ 48wk NCT02738775 · Phase 2 · registry result, not featured evidence 0.14 per year @ 48wk NCT02738775 · Phase 2 · registry result, not featured evidence 0.14 per year @ 48wk NCT02738775 · Phase 2 · registry result, not featured evidence 0 per year @ 48wk NCT02738775 · Phase 2 · registry result, not featured evidence 0 per year @ 48wk NCT02738775 · Phase 2 · registry result, not featured evidence |
| NEDA responder rate · % of participants | 9.8% (n=433) vs 5.1% (n=427) TER @ 104wk20 mgb,c,f NCT02792231 · Phase 3 1 other source trial14.4% (n=428) vs 3.2% (n=413) TER @ 104wk20 mg NCT02792218 · Phase 3 | 44.6% (n=271) vs 15% (n=274) Teriflunomide @ 96wkb,c,f NCT03277261 · Phase 3 · combination 1 other source trial43% (n=272) vs 11.4% (n=272) Teriflunomide @ 96wk NCT03277248 · Phase 3 · combination |
| Dropout rate | 17%20 mgg NCT02792231 · Phase 3 show 26 more results—20mg NCT02792231 · Phase 3 10.5%20 mg NCT02792218 · Phase 3 —20 mg NCT02792218 · Phase 3 19.8%20 mg NCT04486716 · Phase 3 2.9%60 mg q12w NCT01457924 · Phase 2 9.4%60 mg q4w NCT01457924 · Phase 2 6.3%30 mg q12w NCT01457924 · Phase 2 14.7%3 mg q12w NCT01457924 · Phase 2 0%700 mg NCT00640328 · Phase 2 · monotherapy 9.1%300 mg NCT00640328 · Phase 2 · monotherapy 0%100 mg NCT00640328 · Phase 2 · monotherapy 7.6%Ofatumumab NCT05084638 · Phase 4 · registry result, not featured evidence —Ofatumumab-Treated NCT05084638 · Phase 4 · registry result, not featured evidence 4% NCT05199571 · Phase 4 · registry result, not featured evidence —20 mg NCT04353492 · Phase 3 · registry result, not featured evidence 6.9%Ofatumumab NCT04353492 · Phase 3 · registry result, not featured evidence 7%20 mg NCT03249714 · Phase 2 · registry result, not featured evidence —20 mg NCT03249714 · Phase 2 · registry result, not featured evidence —20 mg NCT03249714 · Phase 2 · registry result, not featured evidence —20 mg NCT03560739 · Phase 2 · registry result, not featured evidence —20 mg NCT03560739 · Phase 2 · registry result, not featured evidence 0%20 mg NCT03560739 · Phase 2 · registry result, not featured evidence 0%20 mg NCT03560739 · Phase 2 · registry result, not featured evidence —20 mg NCT03560739 · Phase 2 · registry result, not featured evidence 0.8%20 mg NCT03560739 · Phase 2 · registry result, not featured evidence 0%20 mg NCT03560739 · Phase 2 · registry result, not featured evidence | 12.4%g NCT03277261 · Phase 3 · combination show 7 more results6.6% NCT03277248 · Phase 3 · combination 0%Cohort 1 NCT02738775 · Phase 2 · registry result, not featured evidence 25%Cohort 2 NCT02738775 · Phase 2 · registry result, not featured evidence 0%Cohort 3 NCT02738775 · Phase 2 · registry result, not featured evidence 11.1%Cohort 4 NCT02738775 · Phase 2 · registry result, not featured evidence 0%Cohort 5 NCT02738775 · Phase 2 · registry result, not featured evidence 12.5%Cohort 6 NCT02738775 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 3.1%20 mgg NCT02792231 · Phase 3 show 26 more results—20mg NCT02792231 · Phase 3 3.2%20 mg NCT02792218 · Phase 3 —20 mg NCT02792218 · Phase 3 4.5%20 mg NCT04486716 · Phase 3 0%60 mg q12w NCT01457924 · Phase 2 3.1%60 mg q4w NCT01457924 · Phase 2 3.1%30 mg q12w NCT01457924 · Phase 2 11.8%3 mg q12w NCT01457924 · Phase 2 0%700 mg NCT00640328 · Phase 2 · monotherapy 9.1%300 mg NCT00640328 · Phase 2 · monotherapy 0%100 mg NCT00640328 · Phase 2 · monotherapy —Ofatumumab NCT05084638 · Phase 4 · registry result, not featured evidence —Ofatumumab-Treated NCT05084638 · Phase 4 · registry result, not featured evidence — NCT05199571 · Phase 4 · registry result, not featured evidence —20 mg NCT04353492 · Phase 3 · registry result, not featured evidence 0.5%Ofatumumab NCT04353492 · Phase 3 · registry result, not featured evidence —20 mg NCT03249714 · Phase 2 · registry result, not featured evidence —20 mg NCT03249714 · Phase 2 · registry result, not featured evidence —20 mg NCT03249714 · Phase 2 · registry result, not featured evidence —20 mg NCT03560739 · Phase 2 · registry result, not featured evidence —20 mg NCT03560739 · Phase 2 · registry result, not featured evidence 0%20 mg NCT03560739 · Phase 2 · registry result, not featured evidence 0%20 mg NCT03560739 · Phase 2 · registry result, not featured evidence —20 mg NCT03560739 · Phase 2 · registry result, not featured evidence 0.8%20 mg NCT03560739 · Phase 2 · registry result, not featured evidence 0%20 mg NCT03560739 · Phase 2 · registry result, not featured evidence | 6.2%g NCT03277261 · Phase 3 · combination show 7 more results1.1% NCT03277248 · Phase 3 · combination 0%Cohort 1 NCT02738775 · Phase 2 · registry result, not featured evidence 0%Cohort 2 NCT02738775 · Phase 2 · registry result, not featured evidence 0%Cohort 3 NCT02738775 · Phase 2 · registry result, not featured evidence 11.1%Cohort 4 NCT02738775 · Phase 2 · registry result, not featured evidence 0%Cohort 5 NCT02738775 · Phase 2 · registry result, not featured evidence 0%Cohort 6 NCT02738775 · Phase 2 · registry result, not featured evidence |
| Serious AEs | —20 mgg NCT02792231 · Phase 3 show 26 more results8.7%20mg NCT02792231 · Phase 3 —20 mg NCT02792218 · Phase 3 11%20 mg NCT02792218 · Phase 3 5.9%20 mg NCT04486716 · Phase 3 2.9%60 mg q12w NCT01457924 · Phase 2 6.3%60 mg q4w NCT01457924 · Phase 2 0%30 mg q12w NCT01457924 · Phase 2 2.9%3 mg q12w NCT01457924 · Phase 2 0%700 mg NCT00640328 · Phase 2 · monotherapy 18.2%300 mg NCT00640328 · Phase 2 · monotherapy 0%100 mg NCT00640328 · Phase 2 · monotherapy —Ofatumumab NCT05084638 · Phase 4 · registry result, not featured evidence 6.7%Ofatumumab-Treated NCT05084638 · Phase 4 · registry result, not featured evidence 0% NCT05199571 · Phase 4 · registry result, not featured evidence 6%20 mg NCT04353492 · Phase 3 · registry result, not featured evidence —Ofatumumab NCT04353492 · Phase 3 · registry result, not featured evidence —20 mg NCT03249714 · Phase 2 · registry result, not featured evidence 2.5%20 mg NCT03249714 · Phase 2 · registry result, not featured evidence 2.3%20 mg NCT03249714 · Phase 2 · registry result, not featured evidence 1.6%20 mg NCT03560739 · Phase 2 · registry result, not featured evidence 0%20 mg NCT03560739 · Phase 2 · registry result, not featured evidence —20 mg NCT03560739 · Phase 2 · registry result, not featured evidence —20 mg NCT03560739 · Phase 2 · registry result, not featured evidence 0%20 mg NCT03560739 · Phase 2 · registry result, not featured evidence 3.1%20 mg NCT03560739 · Phase 2 · registry result, not featured evidence —20 mg NCT03560739 · Phase 2 · registry result, not featured evidence | 11.4%g NCT03277261 · Phase 3 · combination show 7 more results10.3% NCT03277248 · Phase 3 · combination 0%Cohort 1 NCT02738775 · Phase 2 · registry result, not featured evidence 12.5%Cohort 2 NCT02738775 · Phase 2 · registry result, not featured evidence 25%Cohort 3 NCT02738775 · Phase 2 · registry result, not featured evidence 0%Cohort 4 NCT02738775 · Phase 2 · registry result, not featured evidence 0%Cohort 5 NCT02738775 · Phase 2 · registry result, not featured evidence 25%Cohort 6 NCT02738775 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 20mgg injection related reaction 24.7% injection related reaction 24.7% nasopharyngitis 18.3% NCT02792231 · Phase 3 show 18 more results3 mg q12w injection related reaction 47.1% urinary tract infection 8.8% anaemia 5.9% NCT01457924 · Phase 2 700 mg rash 57.1% (placebo 50%) throat irritation 28.6% (placebo 0%) upper respiratory tract infection 28.6% (placebo 75%) NCT00640328 · Phase 2 · monotherapy 300 mg throat irritation 36.4% (placebo 0%) rash 27.3% (placebo 50%) viral infection 27.3% (placebo 0%) NCT00640328 · Phase 2 · monotherapy 100 mg nasopharyngitis 50% (placebo 25%) throat irritation 37.5% (placebo 0%) depression 25% (placebo 0%) NCT00640328 · Phase 2 · monotherapy chills 36.1% headache 27.7% myalgia 26.1% NCT05084638 · Phase 4 · registry result, not featured evidence injection related reaction 43.4% covid-19 12.1% upper respiratory tract infection 12.1% NCT05199571 · Phase 4 · registry result, not featured evidence 20 mg injection related reaction 53.4% covid-19 37% nasopharyngitis 17.1% NCT04353492 · Phase 3 · registry result, not featured evidence 20 mg nasopharyngitis 17.5% (placebo 19%) rash 7.5% (placebo 0%) alanine aminotransferase increased 5% (placebo 4.8%) NCT03249714 · Phase 2 · registry result, not featured evidence 20 mg injection related reaction 20.9% (placebo 19%) nasopharyngitis 14% (placebo 19%) oral herpes 9.3% (placebo 0%) NCT03249714 · Phase 2 · registry result, not featured evidence 20 mg injection related reaction 32% headache 10.2% injection site reaction 8.6% NCT03560739 · Phase 2 · registry result, not featured evidence 20 mg injection related reaction 38.5% diarrhoea 7.7% fatigue 7.7% NCT03560739 · Phase 2 · registry result, not featured evidence 20 mg injection related reaction 46.2% asthenia 7.7% cough 7.7% NCT03560739 · Phase 2 · registry result, not featured evidence 20 mg injection related reaction 22.3% injection site reaction 13.1% headache 5.4% NCT03560739 · Phase 2 · registry result, not featured evidence | show 7 more resultsback pain 37.5% (placebo 0%) headache 25% (placebo 15.4%) hypoaesthesia 25% (placebo 7.7%) NCT02738775 · Phase 2 · registry result, not featured evidence dizziness 37.5% (placebo 23.1%) fatigue 37.5% (placebo 38.5%) headache 37.5% (placebo 15.4%) NCT02738775 · Phase 2 · registry result, not featured evidence arthralgia 25% (placebo 7.7%) diarrhoea 25% (placebo 0%) fatigue 25% (placebo 38.5%) NCT02738775 · Phase 2 · registry result, not featured evidence fatigue 50% (placebo 38.5%) nasopharyngitis 37.5% (placebo 0%) sinusitis 37.5% (placebo 15.4%) NCT02738775 · Phase 2 · registry result, not featured evidence dysphagia 37.5% (placebo 15.4%) infusion related reaction 37.5% (placebo 23.1%) throat irritation 37.5% (placebo 15.4%) NCT02738775 · Phase 2 · registry result, not featured evidence nausea 62.5% (placebo 15.4%) dizziness 37.5% (placebo 23.1%) fatigue 37.5% (placebo 38.5%) NCT02738775 · Phase 2 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 3 versus Phase 2.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dThe assessment timepoint is not available for both results.
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fAssessment timepoints differ: 104 weeks versus 96 weeks.
- gPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ofatumumab
show 17 more results
show 5 more results
show 11 more results
show 1 more result
show 6 more results
show 1 more result
show 3 more results
show 3 more results
show 9 more results
show 3 more results
+ 23 further endpoints in the CSV export.
Ublituximab
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 11 more results
show 11 more results
show 5 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ofatumumab's landscape · Ublituximab's landscape